Jazz Pharmaceuticals plc
Jazz Pharmaceuticals Appoints Renee Gala as New CEO
Summary
Jazz Pharmaceuticals plc announced on July 10, 2025, that Renee Gala, its current President and Chief Operating Officer, will succeed Bruce Cozadd as President and Chief Executive Officer, effective August 11, 2025. Concurrently, the Board will increase its size from 12 to 13 members with Gala's appointment as a Class I director. Cozadd, who co-founded the company, will retire from the CEO role but continue as Chairperson. Gala's new role includes a salary increase, bonus adjustment, and additional equity compensation. This transition follows a thorough succession planning process by the Board.
Profitelligence Alerts
Get alerts for JAZZ
Be first to know when Jazz Pharmaceuticals plc files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company that focuses on developing life-changing medicines for patients in various therapeutic areas. The company's primary function is to research, manufacture, and market drugs that address unmet medical needs, particularly in the fields of neuroscience, oncology, and sleep medicine. Jazz Pharmaceuticals has gained prominence for its innovative products such as Xyrem, used for treating narcolepsy, and Vyxeos, a treatment for certain types of leukemia. Headquartered in Dublin, Ireland, the company operates extensively across North America and Europe, working to advance scientific research in pharmaceuticals. By prioritizing patient care and survival, Jazz Pharmaceuticals plays a significant role in the pharmaceutical industry with its commitment to developing novel therapies. Moreover, the company's strategic collaborations and acquisitions enable it to expand its product portfolio and impact the healthcare sector positively. Jazz Pharmaceuticals continues to be a key player in transforming patient care for complex conditions.
Official SEC Documents
Advertisement